

Cytonus Therapeutics Enters Licensing Agreement with Medinno for HIEstem™, a Neuro-Regenerative Cellular Therapy

Cytonus obtains exclusive rights to Medinno's HIEstem for the North American and MENA markets

SAN DIEGO, CALIFORNIA, UNITED STATES, January 9, 2024 /EINPresswire.com/ -- Cytonus Therapeutics, Inc. ("Cytonus") a biotherapeutic company developing transformative medicines based on next generation drug-delivery platform technology called Cargocytes and Medinno, Inc. ("Medinno"), a clinical-stage regenerative medicine company focusing on neurological diseases, today announced that Cytonus has in licensed the North American and Middle Eastern and North African commercial rights to Medinno's HIEstem™ to treat Neonatal Hypoxic Ischemic Encephalopathy (HIE) and Intraventricular Hemorrhage (IVH).

"Licensing Medinno's HIEstem provides Cytonus with a clinically validated cell therapy with a potential first-in-class, best-in-class neuroprotective therapeutic against HIE and IVH, two devastating medical conditions with limited therapeutic options." said Remo Moomiaie-Qajar, M.D., Co-Founder and CEO of Cytonus. "Standard of care for Neonates recently diagnosed with HIE includes hypothermic therapy. Despite this, mortality is reported to be as high as 60% within the first 6 months of life and long-term disabilities are persistent and life altering for most of the children and families. IVH has a worse prognosis, with an expected mortality between 50% to 80%, with current treatments options. These two indications are textbook definitions of unmet medical needs that are very well suited for a stem cell therapeutics."

"We are looking forward to working together with Cytonus not only to develop HIEstem™ in the USA and MENA for Neonate patients. In addition, the two companies will develop sophisticated regenerative-medicine therapeutics with a convergence of Medinno's and Cytonus' state-of-the-art technologies and expertise." said Kyeongmin Joo, MD, PhD. the Founder and CEO of Medinno.

"We are excited about the in licensing of this powerful therapy that has shown great early results in clinical trials." commented Cytonus' executive chairman, Christopher Thorne, JD-MBA, "HIEstem further adds depth to Cytonus' pipeline and is a synergistic addition to one of our key areas of interest in regenerative medicine."

About Neonatal Hypoxic Ischemic Encephalopathy

Hypoxic ischemic encephalopathy (HIE) is a type of brain dysfunction (brain injury) that occurs when the brain experiences a decrease in oxygen or blood flow. HIE can occur before birth,

during labor and delivery or after birth. The amount of time the brain spends without oxygen or blood flow can impact how severely the brain is damaged.

Children who experience mild to moderate effects from HIE can have more severe disability and possible death. Brain injury from HIE can cause developmental delay, cognitive impairment, cerebral palsy or epilepsy. The effects of HIE can become more noticeable as a baby develops. Sometimes, issues are not identified until school-age.

About Neonatal Intraventricular Hemorrhage

Neonatal intraventricular hemorrhage (IVH) is a type of brain hemorrhage that affects the premature newborn infant born at less than 33 weeks of gestation. Current treatment and management of IVH is primarily aimed at preventing preterm birth if possible. However, IVH develops in one third of preterm babies.

Moderate and severe forms of IVH may provoke hydrocephalus, excessive fluid in the brain, that needs further surgical management and may cause life-long seizure, cerebral palsy, deafness, blindness, and other serious neuro-developmental delays.

About Medinno

Medinno Inc. is a South Korea-based biopharmaceutical company specializing in stem cell therapeutics for pediatric and adult CNS diseases. The company's flagship product, HIEstem™, is currently in development for neonate patients facing HIE and IVH, which pose significant life-threatening challenges even with intensive care. Following the successful completion of the Phase 1 Clinical Trial and the attainment of Orphan Drug Designation (ODD) in South Korea, Medinno has also secured Rare Pediatric Disease Designation (RPDD) for HIEstem™ in the United States. The company operates a Good Manufacturing Practice (GMP) facility and is preparing for a global Phase 2 clinical trial for HIEstem™.

For more information, please visit <http://medinno.co.kr/>.

About Cytonus

Cytonus Therapeutics, Inc. is a San Diego-based biotechnology company focused on discovering and advancing novel medicines enabled by the Cargocyte™ Drug Delivery Platform. The company has a pipeline of proprietary immunotherapeutic products to improve patient outcomes for a wide range of medical conditions including cancers, infectious diseases, inflammatory diseases, and cognitive disorders. The Cargocyte-based technologies are next-generation synthetic biology delivery drones that have demonstrated measurable advantages for treating numerous medical applications across unmet therapeutic areas. Cargocytes™ are engineered to safely transport a multiplicity of therapeutic payloads into difficult-to-reach targeted tissues, and can be programmed to deliver selective, potent, and controllable "off-the-shelf" well-validated therapies. These distinctive features demonstrate the potential for Cargocytes to usher in a new era of precision medicine.

For more information, please visit <https://cytonus.com>. Follow Cytonus on LinkedIn and Twitter "X": @CytonusTx.

Notice: Statements in this news release, other than strictly historical facts, such as statements about Cytonus' plans and strategies, new and existing products, and technologies, anticipated clinical and regulatory pathways, and markets for its products, are forward-looking statements. The words "believe," "expect," "aim," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof. Such statements involve risks and uncertainties that could cause actual results to differ materially from anticipated results due to many factors, including regulatory and development risks. The company undertakes no obligation to publicly update or revise any forward-looking statement. This news release is neither an offer to sell, nor the solicitation of any offer to purchase, any security.

Cytonus Therapeutics, Inc.

Cytonus Therapeutics, Inc.

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/679635195>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.